Crossmark

Response to ‘Comment on “Cost-Effectiveness of Niraparib Versus Routine Surveillance, Olaparib and Rucaparib for the Maintenance Treatment of Patients with Ovarian Cancer in the United States”’

Crossref DOI link: https://doi.org/10.1007/s40273-019-00803-7

Published Online: 2019-05-02

Published Print: 2019-07

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Guy, Holly https://orcid.org/0000-0003-1689-8495
Walder, Lydia

Fisher, Mark
Funding

Funding for this research was provided by:

TESARO, Inc.
License Information

Text and Data Mining valid from 2019-05-02
More Information

Article History

First Online: 2 May 2019

Compliance with Ethical Standards

:

: This response was funded by TESARO, Inc.

: Holly Guy, Lydia Walder, and Mark Fisher are employees of FIECON Ltd, a health economics consultancy, which performed the analyses presented in the original article, funded by TESARO, Inc.

Document is current

Any future updates will be listed below